Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 26, 2022- Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent- Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter- Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent- Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent- Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent- R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets- Jan 12, 2022- EnSite™ X EP System with EnSite Omnipolar Technology (OT) provides a 360-degree view of the heart, regardless of catheter orientation, for cardiac mapping without compromise
- Jan 6, 2022- The company announced it's developing a new category of consumer biowearables called Lingo, which is being designed to track key signals in the body - such as glucose, ketones, and lactate - to help people better understand their general health and take action- Abbott is the first healthcare company to headline the Consumer Electronics Show, with Chairman and CEO Robert Ford presenting alongside scientists and inventors, industry partners, influencers and people who use Abbott health tech
- Jan 4, 2022- New U.S. FDA-approved labeling lifts restrictions on 60-centimeter Octrode™ leads, which are implanted, electrically insulated wires that transmit electrical impulses to the target nerves- Expanded MRI compatibility allows more patients to obtain necessary scans and increases efficiencies for radiologists